Bris­tol My­ers bags a long-await­ed FDA OK for ozan­i­mod — but the pan­dem­ic will keep it off the mar­ket

The FDA has come through with the long-await­ed ap­proval of ozan­i­mod, the once top MS drug hope­ful that was side­lined by the agency 2 years ago af­ter Cel­gene was flagged for lame con­duct in fil­ing a drug ap­pli­ca­tion. But the glob­al Covid-19 out­break will keep it on the side­lines for awhile longer.

Now a new prod­uct for Bris­tol My­ers Squibb in the wake of its $74 bil­lion Cel­gene buy­out, the drug will even­tu­al­ly be pit­ted against No­var­tis’ S1P1 ri­val Mayzent, which slipped ahead in the drug de­vel­op­ment race as Cel­gene stum­bled and fell. J&J has its own ri­val in the field, pones­i­mod, which was re­cent­ly filed for an OK of its own.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.